Amy Puerto
Optometrist · Denham Springs, LANPI 1881070498
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,219 of the $9,680 with a category attached, or 64.2%. 22 manufacturers reported payments, led by Alcon at 40.4% of the total. Reporting peaked in 2023 at $3,806 and has fallen 67.9% since, to $1,222 in 2025. Among optometrist clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 130 payments — averaging $74.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$4K
- AbbVie$1K
- Optos, Inc.$575
- Dompe US, Inc.$450
- Bausch & Lomb Americas Inc.$433
- Glaukos Corporation$419
- plus $3K from 16 others
What the payments were for
- Consulting fees$3,12832%
- Food & beverage$6,21964%
- Gifts$190%
- Entertainment$3153%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 23 | $3,909 |
| AbbVie(2 entities) | 29 | $1,098 |
| Optos, Inc. | 5 | $575 |
| Dompe US, Inc. | 5 | $450 |
| Bausch & Lomb Americas Inc. | 8 | $433 |
| Glaukos Corporation | 3 | $419 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 7 | $406 |
| Tarsus Pharmaceuticals, Inc. | 10 | $389 |
| Sun Pharmaceutical Industries Inc. | 7 | $310 |
| Carl Zeiss Meditec USA, Inc. | 2 | $279 |
| Johnson & Johnson Vision Care, Inc. | 4 | $222 |
| Coopervision Inc. | 3 | $207 |
| Oyster Point Pharma, Inc. | 5 | $201 |
| Biotissue Holdings Inc. | 2 | $200 |
| Kala Pharmaceuticals, Inc. | 4 | $154 |
| Harrow Eye, LLC | 2 | $148 |
| Novartis | 6 | $119 |
| Shire North American Group Inc | 1 | $66 |
| Ocular Therapeutix, Inc. | 1 | $29 |
| Aerie Pharmaceuticals, Inc. | 1 | $24 |
| Mallinckrodt Hospital Products Inc. | 1 | $23 |
| Carl Zeiss Meditec AG | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TOTAL30$3,233
- PANORAMIC OPHTHALMOSCOPE$819
- OCT OPHTHALMOSCOPE$698
- DAILIES TOTAL1$563
- Precision 1$563
- Systane$563
- NFC-700$410
- LUMIGAN$407
- INFUSE$344
- VUITY$335
- KXL System$282
- Photrexa$282
- Oxervate$243
- BIOTRUE ONE DAY$237
- ULTRA$226
- BIOTRUE$212
- CEQUA$208
- Acuvue$150
- CIRRUS HD-OCT$147
- Hydrus Microstent$141
How this compares
$9,680 in reported general payments places this provider in the 95th percentile of 500 optometrist providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 12 | $671,151 |
| RestasisCyclosporine | 56 | $52,796 |
| XdemvyLotilaner | 14 | $26,030 |
| Cyclosporine | 26 | $8,546 |
| RocklatanNetarsudil Mesylat/Latanoprost | 22 | $8,249 |
| Prednisolone Acetate | 39 | $1,567 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 62 | $800 |
| Latanoprost | 83 | $674 |
| Doxycycline Hyclate | 22 | $339 |
| Dorzolamide Hcl | 11 | $268 |
| ErythromycinErythromycin Base | 24 | $200 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 23 | $114 |
| Brimonidine Tartrate | 19 | $106 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $450 | $671,15112 claims |
| AbbVieRestasis | $1,098 | $52,79656 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $389 | $26,03014 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $24 | $8,24922 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 500 optometrist providers in Louisiana.
Other optometrist in Denham Springs
- Celeste DicarloDenham Springs$8K
- Pamela TheriotShreveport$207K
- Joshua DavidsonGonzales$189K
- Jeffrey WilhiteMarrero$86K
- Christopher WrotenHammond$59K
- James LamarNew Orleans$45K
- John McCallLogansport$32K
- Robert KellyMarrero$26K
- Shane FontenotJennings$23K
- Stephen LewisShreveport$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.